Topical Tacrolimus 0.03% Ointment for Intractable Allergic Conjunctivitis: An Open Label Pilot Study
This trial is active, not recruiting.
|Treatment||tacrolimus 0.03% ointment (protopic)|
|Sponsor||Assaf-Harofeh Medical Center|
|Trial identifier||NCT00443105, 20050321|
The purpose of this study is to determine the efficacy, tolerance and safety of tacrolimus 0.03% ointment in the treatment of intractable allergic conjunctivitis.
|Intervention model||single group assignment|
Male or female participants at least 5 years old.
Inclusion Criteria: - Subjects included if they were > 5 years old and suffered from intractable allergic conjunctivitis Exclusion Criteria: - pregnancy or breastfeeding,history of herpetic eye disease,transplant patients concomitant administration of drugs inhibiting cytochrome CYP3A4, hypersensitivity to macrolides
|Principal investigator||David Zadok, MD|
Call for more information